Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: MK0954, losartan potassium/Duration of Treatment: 18 weeks (Drug); Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Merck Sharp & Dohme Corp. Official(s) and/or principal investigator(s): Medical Monitor, Study Director, Affiliation: Merck Sharp & Dohme Corp.
Summary
A study to evaluate the effects of combination losartan versus combination atenolol in
patients with ambulatory systolic hypertension.
Clinical Details
Official title: Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Mean daytime ambulatory systolic blood pressure
Secondary outcome: Ambulatory BPPulse pressure Trough sitting BP Percentage of patients who reach goal ambulatory systolic BP
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males or females at least 18 years of age who have ambulatory systolic hypertension.
Locations and Contacts
Additional Information
Related publications: Lacourcière Y, Poirier L, Lefebvre J. Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension. Can J Cardiol. 2007 Apr;23(5):377-82.
Starting date: February 2003
Last updated: March 27, 2015
|